美股A股
StockGist
Back
10-Q2026-05-14· deepseek-chat

YCBD · cbdMD, Inc.

0001437749-26-017042

SEC filing

Summary

Revenue grew 18.8% YoY driven by wholesale expansion and the Bluebird acquisition, but operating losses widened as integration and regulatory costs outpaced topline gains.

Key takeaways

Full analysis

Wholesale Shift and Bluebird Acquisition Drove Top-Line Growth

Margin Compression from Mix and Regulatory Compliance

Operating Loss Widened on Integration and Regulatory Costs

Operating loss widened to -$800.8 thousand from -$485.8 thousand, a 64.8% increase. The increase in operating expenses was driven by higher labor costs tied to the Bluebird acquisition, annual adjustments, and regulatory-related rework projects, partially offset by savings in rent and other miscellaneous expenses. The company remains focused on cost controls and profitability initiatives.

Cash Burn Tripled Despite Working Capital Improvements

EPS Improvement Masked by Capital Structure Changes

Diluted earnings per share improved to -$0.08 from -$1.90, a 95.8% improvement. This improvement is largely attributable to changes in the company's capital structure, including a reverse stock split or share issuances, rather than an improvement in underlying profitability. The net loss per share remains negative.

Regulatory Uncertainty and Going-Concern Risk Loom

The company faces ongoing regulatory uncertainty, particularly with the upcoming Farm Bill considerations. Management acknowledges that while it believes it can execute its strategy and raise additional funds, there can be no assurances. The company continues to focus on growing in a smart, profitable manner with appropriate cost controls.